オハイオにおける潰瘍性大腸炎の臨床試験
オハイオ内の拠点で、潰瘍性大腸炎に関する26件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/01更新 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastro Health Research - Cincinnati, Cincinnati
- DSI Research Northridge LLC, Dayton
- Gastro Health Research - Liberty Township, Liberty Township
- 他3件
被験者募集中第4相
18歳〜80歳 · 全性別 · 2026/09/30更新 · NCT06581328A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
- University Hospitals Cleveland Medical Center /ID# 271831, Cleveland
被験者募集中第3相
2歳〜17歳 · 全性別 · 2026/09/30更新 · NCT07071519A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- GCGA Physicians, LLC dba / Gastro Health Research, Cincinnati
- NexGen Research, Lima
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/30更新 · NCT06598943Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
- Xencor Investigative Site, Beavercreek
被験者募集中第1/2相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/09/29更新 · NCT06619990A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-025, Brunswick
- Site US-023, Dayton
- Site US-027, Westlake
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/29更新 · NCT07845487A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第3相
3歳以上 · 全性別 · 2026/09/25更新 · NCT06663332A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- Cleveland Clinic, Cleveland
被験者募集中第2/3相
2歳〜17歳 · 全性別 · 2026/09/24更新 · NCT05076175Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937086Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Dayton Gastroenterology, LLC, Dayton
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07186101LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- Ohio State University, Hilliard
- DSI Research, LLC d/b/a ObjectiveHealth Clinical Research - Springboro, Springboro
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07415044A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- University of Cincinnati, Cincinnati
- Ohio Gastroenterology group, Inc., Columbus
- Gastro Intestinal Research Institute of Northern Ohio, LLC., Westlake
被験者募集中第4相
18歳〜65歳 · 全性別 · 2026/09/21更新 · NCT06095128Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
- Cleveland Clinic Foundation, Cleveland
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/21更新 · NCT07513181A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Ohio Gastroenterology Group Inc. - Site Number: 8400006, Columbus
- OSU Wexner Medical Center - Site Number: 8400077, Columbus
- North Shore Gastroenterology Research - Site Number: 8400130, Westlake
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/09/15更新 · NCT07185009A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- Great Lakes Gastroenterology Research, LLC, Mentor
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07577856An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Gastroenterology & Hepatology Specialists, Inc. - Site Number: 8400139, Canton
- Ohio Gastroenterology Group Inc. - Site Number: 8400006, Columbus
- OSU Wexner Medical Center - Site Number: 8400077, Columbus
- 他4件
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/08/20更新 · NCT07184996Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of Cincinnati, Cincinnati
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/05更新 · NCT07237516An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
- University of Cincinnati College of Medicine, Cincinnati
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
被験者募集中観察研究
18歳〜64歳 · 全性別 · 2026/07/09更新 · NCT06398626A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
- University Hospitals Cleveland Medical Center Rainbow Babies & Children's Hospital, Cleveland
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第2相
12歳〜17歳 · 全性別 · 2026/07/08更新 · NCT05287126A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Children's Clinic, Cleveland
- Cleveland Clinic, Cleveland
被験者募集中第3相
2歳〜17歳 · 全性別 · 2026/06/22更新 · NCT06405087A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
被験者募集中第3相
2歳以上 · 全性別 · 2026/05/07更新 · NCT05442567ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool
- Gastro Intestinal Research Institute of Northern Ohio,, Westlake
被験者募集中観察研究健康なボランティア歓迎
22歳以上 · 全性別 · 2026/04/28更新 · NCT06810518A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cincinnati
- Mirador Therapeutics Selected Site, Liberty Township
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/03/12更新 · NCT07113522Evaluation of the SMART IBD App in Pediatric IBD
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中
13歳〜17歳 · 全性別 · 2025/11/21更新 · NCT07195123Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- University of Cincinnati, Cincinnati
被験者募集中観察研究
18歳以上 · 全性別 · 2025/05/08更新 · NCT06750731ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。